Neuron23 Raises $100M Series C Financing
Gunderson Dettmer represented client Neuron23, a biotechnology company, in its $100 million Series C financing led by SoftBank Vision Fund 2. Neuron23 focuses on developing precision medicines for genetically defined neurological and immunological diseases. The new capital will be invested in the company's lead programs against leucine-rich repeat kinase 2 (LRRK2) and tyrosine kinase 2 (TYK2), and will also be used to build its clinical development team, precision neuroimmunology platform, and data sciences capabilities.
In the announcement of the transaction, CEO of Neuron23 Nancy Stagliano Ph.D. said, "This round represents a strong endorsement of Neuron23's approach to precision neurology which is extremely gratifying. As exemplified within our LRRK2 Parkinson's disease program, we intend to identify patients, using state-of-the-art machine learning tools, who are most likely to respond to our therapies, increasing the likelihood of success in the clinic and bringing the right medicines to the right patients. The time to innovate in neurodegenerative disease drug development is now, and I am grateful to SoftBank Vision Fund 2 and all our existing investors for their support."
The Gunderson deal team was co-led by Marcia Hatch and Nate Gray and included Gina Marek and Jake Plotnik and Aurora McGuckin.